1 ene 2004 año - FDA approves first "anti-angiogenic" drug, bevacizumab

Descripción:

Bavacizumab is the first of a new generation of targeted drugs that attacked cancer by blocking blood flow to the tumors.

Añadido al timeline:

16 nov 2018

0

0

254

Cancer Dates

fecha: